These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 25626386

  • 1. [Dabigatran and risk of bleeding].
    Hasler S.
    Praxis (Bern 1994); 2015 Jan 28; 104(3):157-8. PubMed ID: 25626386
    [No Abstract] [Full Text] [Related]

  • 2. Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
    Carney EF.
    Nat Rev Nephrol; 2015 Jan 28; 11(1):3. PubMed ID: 25421829
    [No Abstract] [Full Text] [Related]

  • 3. Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation.
    Henriksen DP, Hansen MR, Damkier P.
    JAMA Intern Med; 2015 Jul 28; 175(7):1245. PubMed ID: 26146921
    [No Abstract] [Full Text] [Related]

  • 4. Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation.
    Liu S, Kim CO, Lucyk SN.
    JAMA Intern Med; 2015 Jul 28; 175(7):1244-5. PubMed ID: 26146920
    [No Abstract] [Full Text] [Related]

  • 5. The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.
    Klil-Drori A, Azoulay L.
    JAMA Intern Med; 2015 Jul 28; 175(7):1243-4. PubMed ID: 26146918
    [No Abstract] [Full Text] [Related]

  • 6. Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.
    Hernandez I, Zhang Y.
    JAMA Intern Med; 2015 Jul 28; 175(7):1245-7. PubMed ID: 26146922
    [No Abstract] [Full Text] [Related]

  • 7. The importance of postapproval data for dabigatran.
    Redberg RF.
    JAMA Intern Med; 2015 Jan 28; 175(1):25. PubMed ID: 25365377
    [No Abstract] [Full Text] [Related]

  • 8. One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into Perspective.
    Miyares MA.
    JAMA Intern Med; 2015 Jul 28; 175(7):1242-3. PubMed ID: 26146916
    [No Abstract] [Full Text] [Related]

  • 9. Bleeding in Patients of African Ancestry Using Dabigatran: A Potential Effect of Creatine Kinase.
    Horjus DL, van Montfrans GA, Brewster LM.
    JAMA Intern Med; 2015 Jul 28; 175(7):1243. PubMed ID: 26146917
    [No Abstract] [Full Text] [Related]

  • 10. Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.
    Rockey DC.
    Nat Rev Gastroenterol Hepatol; 2015 Mar 28; 12(3):131-2. PubMed ID: 25601661
    [Abstract] [Full Text] [Related]

  • 11. A Methodological Appraisal of Recent Real-World Data Publications on Dabigatran.
    Zint K, Kreuzer J.
    JAMA Intern Med; 2015 Jul 28; 175(7):1244. PubMed ID: 26146919
    [No Abstract] [Full Text] [Related]

  • 12. Risk of bleeding with dabigatran in atrial fibrillation.
    Hernandez I, Baik SH, Piñera A, Zhang Y.
    JAMA Intern Med; 2015 Jan 28; 175(1):18-24. PubMed ID: 25365537
    [Abstract] [Full Text] [Related]

  • 13. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GY.
    Am J Med; 2014 Jul 28; 127(7):650-656.e5. PubMed ID: 24530792
    [Abstract] [Full Text] [Related]

  • 14. Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Govindarajan R, Salgado E.
    Circulation; 2012 Jan 24; 125(3):e290; author reply e293-4. PubMed ID: 22271856
    [No Abstract] [Full Text] [Related]

  • 15. Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Reiffel JA.
    Circulation; 2012 Jan 24; 125(3):e292; author reply e293-4. PubMed ID: 22271858
    [No Abstract] [Full Text] [Related]

  • 16. Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".
    Reynolds S, Parra D, Rosenstein RS.
    Circulation; 2012 Jan 24; 125(3):e291; author reply e293-4. PubMed ID: 22271857
    [No Abstract] [Full Text] [Related]

  • 17. Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S.
    Circulation; 2013 Nov 19; 128(21):2325-32. PubMed ID: 24081972
    [Abstract] [Full Text] [Related]

  • 18. Dabigatran and postmarketing reports of bleeding.
    Southworth MR, Reichman ME, Unger EF.
    N Engl J Med; 2013 Apr 04; 368(14):1272-4. PubMed ID: 23484796
    [No Abstract] [Full Text] [Related]

  • 19. Risk of major bleeding and the standard doses of dabigatran.
    Antoniazzi S, Berdaï D, Conti V, Clementi E, Salvo F.
    Eur J Intern Med; 2014 Jul 04; 25(6):e73-5. PubMed ID: 24629895
    [No Abstract] [Full Text] [Related]

  • 20. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, Matchar D, Sanchez H.
    Circ Cardiovasc Qual Outcomes; 2013 Sep 01; 6(5):567-74. PubMed ID: 23922182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.